pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Summit Therapeutics Inc. ($SMMT) · news · pharmadog
← back to Summit Therapeutics Inc.
News mentioning $SMMT
54
stories
3d
Summit partners with AstraZeneca and Daiichi; Eccogene earns $50M milestone
endpoints
5d
STAT+: HHS announces new efforts to speed up, expand clinical trials with AI
stat
5d
STAT+: Three biotech updates, including accusations of theft and and a new lobbying leader
stat
6d
AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
biospace
6d
Opinion: America’s biotech race with China must be won at home
stat
6d
STAT+: Beam Therapeutics sues Chinese biotech, VC-backed startup, alleging theft of intellectual property
stat
6d
STAT+: Overton won’t get a vote before midterms
stat
6d
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
stat
6d
Summit snags $2B investment from AstraZeneca, clearing financial overhang
biospace
6d
AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push
biopharma dive
7d
AstraZeneca scales Summit’s PD-1xVEGF strategy with $2B investment to fuel ADC combos
fiercebiotech
7d
AstraZeneca buys a $2B stake in Summit, taking equity in bet on cancer drug
endpoints
7d
Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC
biospace
13d
Compass vows to press on with FDA application despite new trial request
biospace
15d
Citing Replimune approval, experts say localized cancer meds could redefine care
biospace
17d
China plans to transform biotech sector into $522B powerhouse by 2030
biospace
20d
FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival
biospace
20d
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
biopharma dive
20d
GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750M
biospace
20d
GSK lays off 650 staffers amid closure of German vaccine manufacturing site
biospace
21d
Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results
biopharma dive
21d
Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs
biospace
23d
Akeso details survival win for its PD-1xVEGF drug versus Keytruda
endpoints
Sep 3, 26
Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again
biospace
Sep 3, 26
Akeso, Summit cancer drug confirms lung cancer survival benefit
biopharma dive
Aug 26, 26
Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial
biopharma dive
Aug 26, 26
Summit, Akeso tout biliary cancer win for PD-1/VEGF in China—but details are pending
biospace
Aug 26, 26
Akeso, Summit hail ivonescimab's biliary tract cancer win in China-only Phase 3 trial
endpoints
Aug 26, 26
Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate
fiercebiotech
Aug 20, 26
Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future
biospace
← prev
page 1 of 2
next →
